Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Kiniksa Pharmaceuticals, Ltd. (KNSA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/25/2023 |
8-K
| Quarterly results |
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/02/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/01/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 02/22/2022 |
8-K
| Quarterly results|
Docs:
|
"KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue: Product revenue, net $ 18,745 $ — $ 38,544 $ — Operating expenses: Cost of goods sold 3,867 — 9,100 — Collaboration expenses 835 — 835 — Research and development 27,433 37,398 99,297 112,042 Selling, general and administrative 22,741 15,500 85,948 45,321 Total operating expenses 54,876 52,898 195,180 157,363 Loss from operations Interest income 77 30 97 1,134 Loss before provision for income taxes Provision for income taxes Net loss $ $ $ $ Net loss per share attributable to common shareholders —basic and diluted $ $ $ $ Weighted average common shares outstanding—basic and diluted 68,970,730 68,062,007 68,576,810 61,842,722 KINIKSA...",
"Huadong Medicine Investor and Media Contact" |
|
| 01/10/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/03/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement is made and entered into as of January 3, 2022 , by and between Kiniksa Pharmaceuticals Corp., a Delaware corporation , and Eben Tessari . WHEREAS, the operations of the Company and its Affiliates are a complex matter requiring direction and leadership in a variety of arenas; WHEREAS, the Employee is currently serving as the Company’ s Senior Vice President, Chief Business Officer and possesses certain experience and expertise that qualify Employee to provide the direction and leadership required by the Company and its Affiliates; WHEREAS, the Company and the Employee are parties to an Amended and Restated Employment Agreement dated as of May 29, 2018 ; and WHEREAS, the Company and the Employee wish to..." |
|
| 11/01/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Quarterly results|
Docs:
|
"KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 Revenue: Product revenue, net $ 7,704 $ — $ 7,704 $ — Costs and operating expenses: Cost of goods sold 2,466 — 2,466 — Research and development 23,945 22,324 52,628 43,225 Selling, general and administrative 21,848 9,536 42,448 18,022 Total operating expenses 48,259 31,860 97,542 61,247 Loss from operations Interest income 6 266 15 1,055 Loss before provision for income taxes Provision for income taxes Net loss $ $ $ $ Net loss per share attributable to common shareholders—basic and diluted $ $ $ $ Weighted average common shares outstanding—basic and diluted 68,395,703 57,914,105 68,332,943 56,618,397 KINIKSA PHARMACEUTICALS, LTD. SELECTED CON..." |
|
| 07/06/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/12/2021 |
8-K
| Quarterly results |
| 05/04/2021 |
8-K
| Quarterly results |
| 04/28/2021 |
8-K
| Quarterly results |
| 03/03/2021 |
8-K
| Quarterly results |
| 02/23/2021 |
8-K
| Quarterly results |
| 01/11/2021 |
8-K
| Quarterly results |
| 12/22/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/10/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/05/2020 |
8-K
| Quarterly results |
| 10/26/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/30/2020 |
8-K
| Quarterly results |
| 07/28/2020 |
8-K
| Quarterly results |
| 07/24/2020 |
8-K
| Quarterly results |
| 07/15/2020 |
8-K
| Quarterly results |
| 07/07/2020 |
8-K
| Quarterly results |
| 06/29/2020 |
8-K
| Quarterly results |
| 05/18/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 04/28/2020 |
8-K
| Quarterly results |
| 04/22/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
|
|
|